Aguilar RF

Language: Spanish
References: 13
Page: 31-38
PDF size: 126.18 Kb.

ABSTRACT

To paediatric neurologists spasticity in all its forms and localizations has always been a major problem, for which there are few means of treatment (very limited in effect) and the precise indication for rehabilitation treatment. Fortunately, at the present time, new possibilities of treatment are showing us a path to be followed. Of course this treatment are not “curative” in the broad sense of the word, but this treatment together with rehabilitation and whole patient care lead to an improved functional state. This optimism should not lead to false hopes, but stimulate us to keep trying to obtain clinical improvement, together with the continued activity of physiotherapists, rehabilitation, orthopedic and other specialists who should jointly treat these patients. In our experience, treatment with botulinum A toxin (TBA) has been effective in a large proportion of cases treated, and this assessment has been as objective as possible, according to the criterion of several specialists, and the family involved. The patients treated showed objective clinical improvement, to a greater or lesser extent, in 80% of cases by more in experts. These results encourage us to continue using TBA and we hope to acquire greater experience and a longer follow-up period in these patients, so as to obtain more and definite indications.

REFERENCES

1. Aguilar-Rebolledo F, Hernández Si, Rayo MD, Soriano FF, Garcia MLI, Ruiz PJ, etal. Botulinum toxin as a treatment for spasticity and distonia in pediatric cerebral palsy. Gac Med Mex 2001; 137:403-11.

2. Pascual-Pascual SI, Sanchez de Muniain P Roche MC, Pascual-Castroviejo 1. La toxina botulínica en el tratamiento de la parálisis cerebral infantil. Rev Neurol (Barc) 1997; 25:1369-75.

3. Aguilar-Rebolledo F. Técnicas de aplicación de la Toxina Botulínica en espasticidad en niños. Tomado de capítulo 15 libro Espasticidad. Ed. Demsa, 2004 México. pp 47-50

4. Aguilar-Rebolledo F, Uso clínico de la toxina botulínica en enfermedades neurológica del niño y del adulto. Avances en la restauración del sistema nervioso. Vicova Editores S. A, de C. V. México 1994. pp 459-488

5. Sutherland DH. Kaufman KR. Wyatt MP Chambers HG MubarakSJ. Double blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy Gait Posture 1998:10: 1-9

6. Corry IS, Cosgrov AP, Waisn EG, McClean 0, Granam H. Botulinum toxin A in the hemiplegic upper limb: a double blind trial. Develop Med Child Neurol 1997;39: 185-193.

7. Albright AL. Baclofen in the treatment of cerebral palsy. J Child Neurol 1996;11: 77-83.

8. McLaughlin JF, Bjornson KF, Astley SJ, et al Selective dorsa rizotomy: efficacy and safety in an investigator masked randomized clinical trial. Develop Med Child Neurol 1998; 40: 220-232

9. Corry JS, Cosgrove AP, Duffy CM, McNeil S, Taylor TC, Graham HK. Botulinum toxin A compared to stretching casts in the treatment of spastic equines; a randomized prospective trial. J Pediatr Orthop 1998;1: 30-31.

10. Brin MF. Botulinum toxin: chemistry pharmacology toxicity and immunology. Muscle Nerve 1997; 6 (suppl):146-168

11. Ranoux D, Gury C, Fondaral J, Mas JL, Zuber M. Potencias relativas de Botox y Dysport: un estudio doble ciego, aleatorio, cruzado sobre distonía cervical. BMJ 2002; 72: 459-462

12. Koman LA, Mooney BP, WaIker F, Loon JM. Botulinum A neuromuscular blockade in the treatment of lower limp spasticitiy in cerebral palsy: a randomized. double blind, placebo-controlled trial. Botox study group. I Pediatr Orthop 2001;20: 108-115.

13. Aguilar Rebolledo F, Pascual Pascual SI. Tratamientos farmacológicos para la parálisis cerebral. Tratamiento de la espasticidad. Plast & Rest Neurol 2002; 1:23-32.